期刊
EXPERT REVIEW OF CLINICAL IMMUNOLOGY
卷 5, 期 5, 页码 565-575出版社
TAYLOR & FRANCIS LTD
DOI: 10.1586/ECI.09.35
关键词
antibiotics; ataxia-telangiectasia; ataxia-telangiectasia mutated gene; ATM; azithromycin; immunization; immunodeficiency; immunoglobulin
类别
资金
- Wyeth Pharmaceuticals, UK
The immunodeficiency in ataxia-telangiectasia (A-T) is highly variable. Laboratory abnormalities correlate poorly with susceptibility to infection and are almost exclusively restricted to patients with mutations resulting in no A-T mutated kinase activity. Opportunistic infections are unusual but sinopulmonary infections are common and can contribute to the development of pulmonary insufficiency. Preventing lung disease involves maximizing immunity, as well as measures to counteract the tendency to develop pulmonary aspiration, which increases with age. Immunizations should include pneumococcal conjugate, influenza and, in all but the most severely lymphopenic, measles, mumps, rubella, and varicella zoster vaccines. Prophylactic azithromycin is commonly used and believed to be useful, although a firm evidence base for its use in A-T is lacking. Approximately 12-15% of patients require regular immunoglobulin therapy. Further studies are required on potential disease-modulating therapies, such as antioxidants and corticosteroids. Strategies for the modulation of gene transcription remain at the preclinical laboratory stage.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据